BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 33857538)

  • 1. Incidence of a subsequent carbapenem-resistant Enterobacteriaceae infection after previous colonisation or infection: a prospective cohort study.
    Tang SSL; Chee E; Teo JQ; Chlebicki MP; Kwa ALH
    Int J Antimicrob Agents; 2021 Jun; 57(6):106340. PubMed ID: 33857538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk Factors and Molecular Epidemiology of Complicated Intra-Abdominal Infections With Carbapenem-Resistant Enterobacteriaceae: A Multicenter Study in China.
    Liu J; Zhang L; Pan J; Huang M; Li Y; Zhang H; Wang R; Zhao M; Li B; Liu L; Gong Y; Bian J; Li X; Tang Y; Lei M; Chen D
    J Infect Dis; 2020 Mar; 221(Suppl 2):S156-S163. PubMed ID: 32176797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbapenem-resistant Enterobacteriaceae in patients with bacteraemia at tertiary hospitals in South Africa, 2015 to 2018.
    Perovic O; Ismail H; Quan V; Bamford C; Nana T; Chibabhai V; Bhola P; Ramjathan P; Swe Swe-Han K; Wadula J; Whitelaw A; Smith M; Mbelle N; Singh-Moodley A;
    Eur J Clin Microbiol Infect Dis; 2020 Jul; 39(7):1287-1294. PubMed ID: 32124106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors and outcomes associated with the isolation of polymyxin B and carbapenem-resistant Enterobacteriaceae spp.: A case-control study.
    Teo JQ; Chang CW; Leck H; Tang CY; Lee SJ; Cai Y; Ong RT; Koh TH; Tan TT; Kwa AL
    Int J Antimicrob Agents; 2019 May; 53(5):657-662. PubMed ID: 30880229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in the rate of carbapenem-resistant Enterobacteriaceae colonisation or Clostridium difficile infection following frontline treatment with tigecycline vs. meropenem for intra-abdominal infections.
    Bartoletti M; Tedeschi S; Pascale R; Raumer L; Maraolo AE; Palmiero G; Tumietto F; Cristini F; Ambretti S; Giannella M; Lewis RE; Viale P
    Int J Antimicrob Agents; 2018 Mar; 51(3):516-521. PubMed ID: 29410250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and Molecular Epidemiology of Carbapenem-Resistant Enterobacteriaceae Among Adult Inpatients in Singapore.
    Marimuthu K; Venkatachalam I; Khong WX; Koh TH; Cherng BPZ; Van La M; De PP; Krishnan PU; Tan TY; Choon RFK; Pada SK; Lam CW; Ooi ST; Deepak RN; Smitasin N; Tan EL; Lee JJ; Kurup A; Young B; Sim NTW; Thoon KC; Fisher D; Ling ML; Peng BAS; Teo YY; Hsu LY; Lin RTP; Ong RT; Teo J; Ng OT;
    Clin Infect Dis; 2017 May; 64(suppl_2):S68-S75. PubMed ID: 28475792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk Factors for Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae (CP-CRE) Acquisition Among Contacts of Newly Diagnosed CP-CRE Patients.
    Schwartz-Neiderman A; Braun T; Fallach N; Schwartz D; Carmeli Y; Schechner V
    Infect Control Hosp Epidemiol; 2016 Oct; 37(10):1219-25. PubMed ID: 27452597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asymptomatic rectal carriage of blaKPC producing carbapenem-resistant Enterobacteriaceae: who is prone to become clinically infected?
    Schechner V; Kotlovsky T; Kazma M; Mishali H; Schwartz D; Navon-Venezia S; Schwaber MJ; Carmeli Y
    Clin Microbiol Infect; 2013 May; 19(5):451-6. PubMed ID: 22563800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network.
    Zhang Y; Wang Q; Yin Y; Chen H; Jin L; Gu B; Xie L; Yang C; Ma X; Li H; Li W; Zhang X; Liao K; Man S; Wang S; Wen H; Li B; Guo Z; Tian J; Pei F; Liu L; Zhang L; Zou C; Hu T; Cai J; Yang H; Huang J; Jia X; Huang W; Cao B; Wang H
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacterial characteristics of carbapenem-resistant Enterobacteriaceae (CRE) colonized strains and their correlation with subsequent infection.
    Lin Q; Wang Y; Yu J; Li S; Zhang Y; Wang H; Lai X; Liu D; Mao L; Luo Y; Tang G; Chen Z; Sun Z
    BMC Infect Dis; 2021 Jul; 21(1):638. PubMed ID: 34215214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germs of thrones - spontaneous decolonization of Carbapenem-Resistant Enterobacteriaceae (CRE) and Vancomycin-Resistant Enterococci (VRE) in Western Europe: is this myth or reality?
    Davido B; Moussiegt A; Dinh A; Bouchand F; Matt M; Senard O; Deconinck L; Espinasse F; Lawrence C; Fortineau N; Saleh-Mghir A; Caballero S; Escaut L; Salomon J
    Antimicrob Resist Infect Control; 2018; 7():100. PubMed ID: 30123500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated to prevalence and treatment of carbapenem-resistant Enterobacteriaceae infections: a seven years retrospective study in three tertiary care hospitals.
    Pang F; Jia XQ; Zhao QG; Zhang Y
    Ann Clin Microbiol Antimicrob; 2018 Mar; 17(1):13. PubMed ID: 29571291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for acquisition of carbapenemase-producing versus non-carbapenemase-producing enterobacterales: a case-control study.
    Hassoun-Kheir N; Hussein K; Karram M; Saffuri M; Badaan S; Peleg S; de Kraker MEA; Aboelhega W; Warman S; Alon T; Eluk O; Geffen Y; Paul M
    Clin Microbiol Infect; 2023 May; 29(5):629-634. PubMed ID: 36641053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology of multidrug-resistant Enterobacteriaceae in Sri Lanka: First evidence of bla
    Kumudunie WGM; Wijesooriya LI; Namalie KD; Sunil-Chandra NP; Wijayasinghe YS
    J Infect Public Health; 2020 Sep; 13(9):1330-1335. PubMed ID: 32439355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology and risk factors for carbapenem-resistant Enterobacteriaceae colonisation and infections: case-controlled study from an academic medical center in a southern area of China.
    Fang L; Lu X; Xu H; Ma X; Chen Y; Liu Y; Hong G; Liang X
    Pathog Dis; 2019 Jun; 77(4):. PubMed ID: 31281931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fast and expensive (PCR) or cheap and slow (culture)? A mathematical modelling study to explore screening for carbapenem resistance in UK hospitals.
    Knight GM; Dyakova E; Mookerjee S; Davies F; Brannigan ET; Otter JA; Holmes AH
    BMC Med; 2018 Aug; 16(1):141. PubMed ID: 30111322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia.
    Tamma PD; Goodman KE; Harris AD; Tekle T; Roberts A; Taiwo A; Simner PJ
    Clin Infect Dis; 2017 Feb; 64(3):257-264. PubMed ID: 28013264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Double-Carbapenem Regimen in the Treatment of Infections due to Carbapenemase Producing Carbapenem-Resistant
    Cancelli F; Oliva A; De Angelis M; Mascellino MT; Mastroianni CM; Vullo V
    Biomed Res Int; 2018; 2018():2785696. PubMed ID: 30581848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbapenem-resistant Enterobacteriaceae colonization and infection in critically ill patients: a retrospective matched cohort comparison with non-carriers.
    Dickstein Y; Edelman R; Dror T; Hussein K; Bar-Lavie Y; Paul M
    J Hosp Infect; 2016 Sep; 94(1):54-9. PubMed ID: 27392978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characterization of carbapenem-resistant
    Yan WJ; Jing N; Wang SM; Xu JH; Yuan YH; Zhang Q; Li AL; Chen LH; Zhang JF; Ma B; Ma Q; Li Y
    J Med Microbiol; 2021 Mar; 70(3):. PubMed ID: 33587030
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.